Graham Capital Management, L.P. Regeneron Pharmaceuticals, Inc. Transaction History
Graham Capital Management, L.P.
- $3.11 Billion
- Q2 2024
A detailed history of Graham Capital Management, L.P. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 389 shares of REGN stock, worth $320,722. This represents 0.01% of its overall portfolio holdings.
Number of Shares
389
Previous 1,538
74.71%
Holding current value
$320,722
Previous $1.48 Million
72.43%
% of portfolio
0.01%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding REGN
# of Institutions
1,492Shares Held
85.8MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.42 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.96 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$6.17 Billion0.65% of portfolio
-
State Street Corp Boston, MA4.84MShares$3.99 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.82 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $88.4B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...